These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23665133)

  • 1. Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission.
    Conter HJ; Lim ZD; Ng CS; Millikan RE; Tannir NM
    Clin Genitourin Cancer; 2013 Sep; 11(3):370-3. PubMed ID: 23665133
    [No Abstract]   [Full Text] [Related]  

  • 2. Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine.
    Fujiwara Y; Kiura K; Tabata M; Takigawa N; Hotta K; Umemura S; Omori M; Gemba K; Ueoka H; Tanimoto M
    Anticancer Drugs; 2008 Apr; 19(4):431-3. PubMed ID: 18454054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
    Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
    J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).
    Buti S; Brighenti M; Bongiovanni C; Buzio C; Chiesa MD; Alberici F; Passalacqua R
    J Immunother; 2007 Oct; 30(7):780-6. PubMed ID: 17893570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
    Ryan CW; Vogelzang NJ; Stadler WM
    Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine.
    Tippin DB; Reeves W; Vogelzang NJ
    J Urol; 1999 Jul; 162(1):155-6. PubMed ID: 10379761
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapeutic response with single agent gemcitabine in metastatic Bellini duct tumor.
    Slovin SF; Berg W; Olgac S; Reuter V; Scher H
    Cancer Invest; 2004; 22(5):818-21. PubMed ID: 15581064
    [No Abstract]   [Full Text] [Related]  

  • 8. Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
    Walter B; Schrettenbrunner I; Vogelhuber M; Grassinger J; Bross K; Wilke J; Suedhoff T; Berand A; Wieland WF; Rogenhofer S; Andreesen R; Reichle A
    Med Oncol; 2012 Jun; 29(2):799-805. PubMed ID: 21607771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
    Amato RJ; Khan M
    Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA phenotype and cytokine-induced tumor control in advanced renal cell cancer.
    Franzke A; Buer J; Probst-Kepper M; Lindig C; Framzle M; Schrader AJ; Ganser A; Atzpodien J
    Cancer Biother Radiopharm; 2001 Oct; 16(5):401-9. PubMed ID: 11776757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy in metastatic renal cell carcinoma.
    Rohrmann K; Staehler M; Haseke N; Bachmann A; Stief CG; Siebels M
    World J Urol; 2005 Jul; 23(3):196-201. PubMed ID: 15806434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine in pre-treated advanced renal carcinoma: a feasibility study.
    Casali M; Marcellini M; Casali A; Giuntini T; Galante E; Ferrone C
    J Exp Clin Cancer Res; 2001 Jun; 20(2):195-8. PubMed ID: 11484974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
    Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
    Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
    Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
    Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
    Richey SL; Ng C; Lim ZD; Jonasch E; Tannir NM
    J Clin Oncol; 2011 Mar; 29(8):e203-5. PubMed ID: 21172884
    [No Abstract]   [Full Text] [Related]  

  • 16. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
    Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF
    Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.
    Stadler WM; Huo D; George C; Yang X; Ryan CW; Karrison T; Zimmerman TM; Vogelzang NJ
    J Urol; 2003 Oct; 170(4 Pt 1):1141-5. PubMed ID: 14501711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
    Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
    Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
    Sella A; Kilbourn RG; Gray I; Finn L; Zukiwski AA; Ellerhorst J; Amato RJ; Logothetis CJ
    Cancer Biother; 1994; 9(2):103-11. PubMed ID: 7812360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.
    Hofmockel G; Langer W; Theiss M; Gruss A; Frohmüller HG
    J Urol; 1996 Jul; 156(1):18-21. PubMed ID: 8648791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.